
San Diego-based Crinetics Pharmaceuticals develops therapeutics for endocrine diseases and cancers.
Founded in San Diego, Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing therapeutics for endocrine diseases and cancers. The company's core mission is to provide effective disease control and simplify the lives of patients with these conditions. Crinetics collaborates with healthcare practitioners to address real medical needs and aims to create value for investors by filling significant market gaps.
Crinetics Pharmaceuticals has attracted notable investors and industry experts, contributing to its growing reputation in the biotech sector. The company has achieved key milestones in its clinical trials, advancing several promising drug candidates. Its overall impact lies in its commitment to addressing unmet medical needs, thereby improving patient outcomes and advancing the field of endocrine therapeutics.

Neurocrine B
neurocrine.com

Innocrin Pharmaceuticals
innocrinpharma.com

CinRx Pharma
cinrx.com

Xeris Biopharma Holdings

KinDex Pharmaceuticals

Escient Pharmaceuticals

G1 Therapeutics
g1therapeutics.com

Eikon Therapeutics
eikontx.com

Sorrento Therapeutics

Chromis Therapeutics

Kronos Bio

Kiniksa Pharmaceuticals
kiniksa.com

Corcept Therapeutics
corcept.com

Innovo Therapeutics

Catalyst Pharmaceuticals
catalystpharma.com
Companies similar to Crinetics Pharmaceuticals include Neurocrine B, Innocrin Pharmaceuticals, CinRx Pharma and Xeris Biopharma Holdings.
Crinetics Pharmaceuticals was founded in 2008.
Crinetics Pharmaceuticals' headquarters is located in San Diego, CA, US.
Crinetics Pharmaceuticals' most recent funding round was for $350M (USD) in September 2023.
As of Sep 13, 2023, Crinetics Pharmaceuticals has raised a total of $796M (USD).
Crinetics Pharmaceuticals has 210 employees as of Feb 6, 2024.